Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOLFIRI + FOLFOX + bevacizumab
- Development stage
- Phase 3
- Lead developer
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
FOLFIRI + FOLFOX + bevacizumab is a sequential chemotherapy treatment strategy evaluated in the ITACa (Italian Trial in Advanced Colorectal Cancer) Phase III trial for the treatment of metastatic colorectal cancer. This regimen combines two standard cytotoxic chemotherapy protocols—FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil) and FOLFOX (oxaliplatin, leucovorin, and 5-fluorouracil)—with bevacizumab, a recombinant humanized monoclonal antibody. Bevacizumab acts as an angiogenesis inhibitor by specifically binding to the vascular endothelial growth factor (VEGF) protein, thereby preventing its interaction with receptors on the surface of endothelial cells. The cytotoxic components work by inhibiting DNA topoisomerase I (irinotecan), inhibiting thymidylate synthase (5-fluorouracil), and forming DNA cross-links (oxaliplatin). The ITACa trial, sponsored by the Istituto Romagnolo per lo Studio dei Tumori (IRST), investigated the optimal sequencing of these agents to improve progression-free and overall survival in patients with advanced colorectal disease.
- Brand names
- CamptosarEloxatinAdrucil
- Other names
- FOLFIRI plus bevacizumabFOLFOX plus bevacizumab
02
Targets
Beyond the preview
Go deeper on FOLFIRI + FOLFOX + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOLFIRI + FOLFOX + bevacizumab.